SARS-CoV-2 Infection in Women and Children

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1602

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
Interests: microbiology; molecular biology; virology

Special Issue Information

Dear Colleagues,

In the context of the COVID-19 pandemic, the world is stepping up efforts to develop vaccines that can help boost herd immunity. Currently approved vaccines require extensive testing to confirm their safety for large-scale use in the general population. However, clinical trials have failed to test the safety and effectiveness of COVID-19 vaccines in people with weakened immune systems, especially in pregnant women.

The SARS-CoV-2 vaccine has been recommended for pregnant women, but survey studies show wildly different results around the world in terms of the willingness to be vaccinated during pregnancy. The cumulative uptake of the SARS-CoV-2 vaccine among pregnant women appears to remain low. A lack of information on the impact of vaccination during pregnancy on fetal safety is one of the most important factors preventing pregnant women from being immunized, thereby preventing herd immunity from being achieved.

Vaccinating as many people as possible is crucial if we are to rebuild a normal way of life. Vaccination campaigns are urgently needed to increase confidence in vaccines to help reduce the spread of infection and possible consequences during pregnancy.

This Special Issue focuses on the immune response of vaccinated pregnant women, the safety and efficacy of COVID-19 vaccination during pregnancy, and the vaccine’s impact on maternal and fetal immune responses. We welcome all types of submissions, including original research, reviews, case reports, etc., for this Special Issue. We look forward to receiving your contributions!

Dr. Narayanaiah Cheedarla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • COVID-19
  • SARS-CoV-2
  • vaccination
  • pregnant women
  • children
  • infants
  • risk groups
  • immune response
  • antibodies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3624 KiB  
Article
Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency
by Chia-Jung Chiang, Wei-Lun Hsu, Mei-Tsz Su, Wen-Chien Ko, Keng-Fu Hsu and Pei-Yin Tsai
Vaccines 2024, 12(2), 164; https://doi.org/10.3390/vaccines12020164 - 5 Feb 2024
Viewed by 1276
Abstract
A pregnancy booster dose significantly reduces the risk and severity of COVID-19, and it is widely recommended. A prospective cohort study was conducted to compare the transplacental passage of maternal antibodies from vaccination or infection during three trimesters against both the vaccine-targeted Wuhan [...] Read more.
A pregnancy booster dose significantly reduces the risk and severity of COVID-19, and it is widely recommended. A prospective cohort study was conducted to compare the transplacental passage of maternal antibodies from vaccination or infection during three trimesters against both the vaccine-targeted Wuhan strain and the Omicron strain of SARS-CoV-2. Maternal–infant dyads from vaccinated mothers were collected between 6 June 2022 and 20 September 2022. We analyzed 38 maternal–infant dyads from mothers who had been infected with COVID-19 and 37 from mothers without any previous infection. Pregnant women who received their last COVID-19 vaccine dose in the third trimester exhibited the highest anti-spike protein antibody levels and neutralizing potency against both the Wuhan strain and Omicron BA.2 variant in their maternal and cord plasma. Both second- and third-trimester vaccination could lead to a higher level of neutralization against the Wuhan and Omicron strains. COVID-19 infection had a negative effect on the transplacental transfer ratio of SARS-CoV-2 antibodies. A booster dose during the second or third trimester is encouraged for the maximum transplacental transfer of humoral protection against COVID-19 for infants. Full article
(This article belongs to the Special Issue SARS-CoV-2 Infection in Women and Children)
Show Figures

Graphical abstract

Back to TopTop